{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 6:', 'Hepatic Assessments in Patients who Experience LFT Elevations', 'Extended Hepatic Panel', 'Herpes Simplex Virus 1 and 2 antibody IgM, IgG', 'Herpes Zoster Virus IgM, IgG', 'HIV 1 and 2a', 'HHV-6', 'Cytomegalovirus antibodies, IgM, IgG', 'HBs Ag, HBc antibody IgM and IgG', 'Anti-nuclear antibodies', 'Epstein-Barr Virus antibodies, IgM and IgG', 'Anti-smooth muscle antibodies', 'Anti-mitochondrial antibodies', 'HCV antibody', 'HAV antibody IgM', 'HCV RNA PCR - qualitative and quantitative', 'HEV antibody IgM', 'Imaging', 'Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant', 'Focused Medical and Travel History', 'Use of any potentially hepatotoxic concomitant', 'medications, including over the counter medications', 'and herbal remedies', 'Alcohol consumption', 'Other potentially hepatotoxic agents including any', 'Recent travels to areas where hepatitis A or E is', 'work-related exposures', 'endemic', 'Note: All assessments will be measured in central laboratory. The full panel of assessments should only be performed once;', 'individual assessments may be repeated, as needed.', 'Abbreviations: CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBs Ag=hepatitis B', 'virus surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV-6=human herpesvirus 6; HIV=human', 'immunodeficiency virus; IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; MRI=magnetic', 'resonance imagery; PCR=polymerase chain reaction; PT=prothrombin time; RNA=ribonucleic acid', 'a HIV testing will not be performed where prohibited by local regulations.', '7.5.5.2.', 'Immunogenicity', 'Blood samples will be collected to evaluate antidrug antibodies (ADAs) to fitusiran. Blood', 'samples for ADA testing must be collected within 4 hours before IMP administration as', 'specified in the Schedule of Assessments (Table 1). In addition, a blood sample to evaluate', 'ADAs will be collected at the ET visit, if applicable.', 'Details regarding the processing, shipping, and analysis of the samples are provided in the', 'Laboratory Manual.', '7.5.6.', 'Adverse Events', '7.5.6.1.', 'Definitions', 'Adverse Event', 'According to the International Conference on Harmonisation (ICH) E2A guideline Definitions', 'and Standards for Expedited Reporting, and 21 Code of Federal Regulations (CFR) 312.32, IND', 'Safety Reporting, an AE is any untoward medical occurrence in a patient or clinical', 'Property of the Sanofi Group - strictly confidential', '60', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'investigational subject administered a medicinal product and which does not necessarily have a', 'causal relationship with this treatment. Since bleeding episodes are recorded as an efficacy', 'assessment of fitusiran, these will not be treated as AEs unless they meet any of the SAE criteria', 'listed in Section 7.5.6.1.', 'Serious Adverse Event', 'An SAE is any untoward medical occurrence that at any dose:', 'Results in death', 'Is life-threatening (an event which places the patient at immediate risk of death from', 'the event as it occurred. It does not include an event that had it occurred in a more', 'severe form might have caused death.)', 'Requires in-patient hospitalization or prolongation of existing hospitalization', 'Results in persistent or significant disability or incapacity', 'Is a congenital anomaly or birth defect', 'Is an important medical event that may not be immediately life-threatening or result', 'in death or hospitalization but may jeopardize the patient and may require', 'intervention to prevent one of the other outcomes listed in the definition above (eg,', 'events include allergic bronchospasm requiring intensive treatment in an emergency', 'room or at home, blood dyscrasias, convulsions, or the development of drug', 'dependency or abuse)', 'Bleeding episodes will be recorded as an efficacy assessment of fitusiran and will not', 'be treated as AEs unless they meet any of the above criteria for SAEs.', 'Adverse Events of Special Interest', 'The following events are considered to be AEs of special interest (AESI):', 'ALT or AST elevations >3x ULN', 'Suspected or confirmed thrombosis', 'Severe or serious ISRs; ISRs that are associated with a recall phenomenon (reaction', 'at the site of a prior injection with subsequent injections), or those that lead to', 'temporary dose interruption or permanent discontinuation of fitusiran', 'Systemic injection associated reactions (IARs), defined as hypersensitivity reactions', 'which are related or possibly related to IMP.', 'Property of the Sanofi Group - strictly confidential', '61', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}